Business
Trading update
Trading update.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n Hikma Pharmaceuticals Plc\n24 October 2006\n\n\n\n Hikma Pharmaceuticals - Trading update\n\nLONDON, 24 October 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK), the\nmultinational pharmaceuticals group, is today updating the market on the Group's\ncurrent trading performance.\n\nOur Branded and Injectables businesses continue to perform well and it is\nexpected that both will deliver strong growth for the full year. However, in the\nGeneric business we have seen decreasing wholesaler inventories and a lower than\nforecast contribution from new product launches. It is therefore now expected\nthat full year Generic sales will be slightly below those achieved in 2005.\n\nThe Group will issue a further update prior to entering its close period in\nJanuary 2007.\n\n - ENDS -\nEnquiries:\n\nHikma Pharmaceuticals PLC\nSusan Ringdal +44 20 7399 2760\nInvestor Relations Director\n\nBrunswick Group\nJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959\n\n\nAbout Hikma\nHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on\ndeveloping, manufacturing and marketing a broad range of both branded and\nnon-branded generic and in-licensed pharmaceutical products. Hikma's operations\nare conducted through three businesses: Generic, Branded and Injectable\nPharmaceuticals. Hikma's operations are based principally in the United States,\nthe Middle East and North Africa ('MENA') region and Europe. In 2005, the Group\nhad revenue of $262 million and profit attributable to shareholders of $44\nmillion. At 31 December 2005, the Group had over 1,800 employees. For news and\nother information, please visit www.hikma.com.\n\n\n\n\n This information is provided by RNS\n The company news service from the London Stock Exchange\n \n ","length":2058,"tagName":"div"}]